Michelle Min, MD, MS, reviewed best practices for managing cutaneous lupus and discussed emerging therapies practitioners ...
Dr Hamzavi discussed how to navigate conversations with patients with HS regarding common misconceptions, expectations with ...
Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...
Phase 3b TOGETHER trial results presented at FC26 show concomitant ixekizumab and tirzepatide significantly improve joint and skin outcomes while driving meaningful weight loss in patients with ...
Investigators studied treatment patterns among patients with generalized pustular psoriasis (GPP) to determine the use of GPP-specific therapies. Corticosteroids remained the primary therapy overall, ...
Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...
Panelists highlight major 2026 approvals, novel oral therapies, expanded pediatric indications, and new severity definitions shaping clinical practice. Recent advances have changed clinical practice ...
Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...
BRAVE-AA-PEDS data presented at FC26 show baricitinib maintained significant hair regrowth through 76 weeks in adolescents ...
Creams, sprays and washes that promise relief from genital herpes are easy to order online, but none of them are FDA-approved.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results